Clinical trial Recruiting at 1 site Interventional Ages 19 and up Women only

At-home electrical stimulation treatment for stress urinary incontinence in women

Official title: A Multi-center, Prospective, Randomized, Double-blind, Sham Device Controlled Clinical Trial to Compare and Evaluate the Efficacy and Safety of the Use an Investigational Device (Model Name CGM MUIT-2301) and Sham Device (Model Name CGM MUIT-2301C) for Female Patients With Stress Urinary Incontinence

Run by Ceragem Inc. · NCT07440927 · Data updated 2026-11-12

This trial will test whether a non-implantable at-home electrical stimulation device can reduce urine leakage in women with stress urinary incontinence.

More Stress Urinary Incontinence (SUI) trials

Quick facts

Study typeInterventional
Ages19 Years and up
SexWomen only
Enrollment96 (estimated)
SponsorCeragem Inc.
Industry-sponsored
Locations1 site (Seoul)
StatusRecruiting
StartedDecember 13, 2024
Main results expectedSeptember 30, 2026
Study endsSeptember 30, 2026
Registry record updatedFebruary 27, 2026
Trial IDNCT07440927 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Women with stress urinary incontinence who have at least 1 g of leakage on the standardized pad test and who can follow twice-daily at-home sessions and attend study visits are ideal candidates.

Probably not a fit

Patients whose leakage is mainly due to urgency or overflow incontinence, or those with less than 1 g on the pad test, are unlikely to benefit from this device.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized, double-blind, sham-controlled multicenter trial enrolling women with stress urinary incontinence. Participants are assigned to either a non-implantable neuromuscular electrical stimulation device or a sham device and self-administer treatment at home twice daily for 15 minutes, at least five days per week, for 12 weeks. The primary outcome is the proportion of patients whose leakage falls below 1 g on the standardized pad test at Week 12. Patients with predominant urgency or overflow incontinence are excluded and must complete baseline and follow-up visits at the study site.

Why it matters

Potential benefit: If successful, the device could substantially reduce or eliminate stress-related urine leakage and offer a convenient non-surgical at-home option.

How similar studies have gone: Previous randomized trials of home pelvic-floor electrical stimulation have shown mixed but generally promising reductions in stress-related urine leakage.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients with urine leakage of ≥1 g on the standardized pad test

Exclusion Criteria:

* Patients with mixed urinary incontinence with predominant urgency urinary incontinence
* Patients with stress urinary incontinence
* Patients with overflow urinary incontinence

Where it's running

  • Samsung Seoul Hospital
    Seoul, South Korea
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.